Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Mind medicine inc (sub voting) crawled time : 12:00 save search
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
Published: 2023-10-26 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: -0.77%
H: 2.33%
C: 0.39%
conference business update financial results
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Published: 2023-10-24 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 2.28%
H: 3.72%
C: 0.74%
mm-120 trial
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
Published: 2023-10-03 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: -0.65%
H: 0.0%
C: -2.3%
mm-402 congress preclinical
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Published: 2023-09-14 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 0.74%
H: 6.37%
C: 5.64%
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
Published: 2023-09-12 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 0.7%
H: 3.92%
C: -2.76%
mm-120 trial
MindMed to Participate at September Investor Conferences
Published: 2023-08-28 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 1.32%
H: 3.12%
C: -1.04%
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
Published: 2023-08-14 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 0.23%
H: 5.85%
C: 4.68%
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
Published: 2023-08-03 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 0.22%
H: 4.72%
C: 2.39%
mm-120 zydis license technology agreement
MindMed to Host Investor Day June 2023
Published: 2023-06-07 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: -0.28%
H: 7.0%
C: 1.4%
day
Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
Published: 2023-06-05 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 1.01%
H: 3.44%
C: 0.86%
six
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
Published: 2023-05-25 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 0.88%
H: 0.0%
C: -2.9%
mm-120 fda drug report
MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update
Published: 2022-11-03 (Crawled : 12:00) - prnewswire.com
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 0.0%
H: 3.58%
C: 3.23%
financial update results
MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
Published: 2022-10-04 (Crawled : 12:00) - prnewswire.com
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 1.21%
H: 4.78%
C: 4.48%
trial phase 1
MindMed Collaborators Dose First Subject in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
Published: 2022-09-20 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: -0.68%
H: 0.41%
C: -4.76%
trial phase 1
MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
Published: 2022-09-20 (Crawled : 12:00) - biospace.com/
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: -0.68%
H: 0.41%
C: -4.76%
trial phase 1
MindMed Announces Compliance with Nasdaq Listing Requirements
Published: 2022-09-14 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 0.13%
H: 2.0%
C: -0.13%
nasdaq
MindMed Collaborators’ Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
Published: 2022-09-08 (Crawled : 12:00) - mindmed.co
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 2.02%
H: 7.67%
C: 7.33%
trial
MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
Published: 2022-09-08 (Crawled : 12:00) - prnewswire.com
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 2.02%
H: 7.67%
C: 7.33%
trial positive results
MindMed to Participate in H.C. Wainwright Global Investment Conference
Published: 2022-09-07 (Crawled : 12:00) - prnewswire.com
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: -1.43%
H: 0.0%
C: -5.7%
global conference
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
Published: 2022-08-25 (Crawled : 12:00) - biospace.com/
MNMD | $8.885 2.36% 2.31% 1.2M
|
n/a
|
| O: 3.46%
H: 0.88%
C: -7.45%
mm-120 trial phase 2b
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.